Delving into the Latest Updates on HRS-9563 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target-

Mechanism-

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Hypertension, mild

Inactive Indication-

Originator Organization

Fujian Suncadia Pharmaceuticals Co Ltd.

Active Organization

Fujian Suncadia Pharmaceuticals Co Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的： 1.评价HRS-9563在高血压受试者中单次皮下注射给药的安全性和耐受性次要目的： 1.评价HRS-9563在高血压受试者中单次皮下注射给药的药代动力学（PK）特征 2.评价HRS-9563在高血压受试者中单次皮下注射给药的药效学（PD）特征 3.评价HRS-9563在高血压受试者中单次皮下注射给药的免疫原性特征

[Translation]

Primary objectives: 1. To evaluate the safety and tolerability of a single subcutaneous injection of HRS-9563 in hypertensive subjects Secondary objectives: 1. To evaluate the pharmacokinetic (PK) characteristics of a single subcutaneous injection of HRS-9563 in hypertensive subjects 2. To evaluate the pharmacodynamic (PD) characteristics of a single subcutaneous injection of HRS-9563 in hypertensive subjects 3. To evaluate the immunogenicity characteristics of a single subcutaneous injection of HRS-9563 in hypertensive subjects

Start Date-

Sponsor / Collaborator

Fujian Suncadia Pharmaceuticals Co Ltd.

100 Clinical Results associated with HRS-9563

Login to view more data

100 Translational Medicine associated with HRS-9563

Login to view more data

100 Patents (Medical) associated with HRS-9563

Login to view more data

100 Deals associated with HRS-9563

Login to view more data